Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

281. Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient?

Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? – Clinical Correlations Search Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? January 20, 2010 6 min read | | Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved. Electronic ISSN 1944-0030. The content of this site is intended for health

2010 Clinical Correlations

282. Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis

Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

283. Anticoagulation for Venous Thromboembolism

Anticoagulation for Venous Thromboembolism Anticoagulation for Venous Thromboembolism – TheNNTTheNNT Anticoagulation Given for Acute Venous Thromboembolism (Deep Venous Thrombosis and Pulmonary Embolism) Unclear benefits vs. harms In Summary, for those who got the anticoagulation: Benefits in NNT 100% saw no benefit 0% were helped by being saved from death None were helped (life saved, preventing pulmonary embolism) Harms in NNT 0.9% were harmed by a major bleeding event 0.9% were harmed (...) addressing whether anticoagulation improves important clinical outcomes in patients with VTE (Nielson et al., 1994). Subjects were enrolled if they were ambulatory with symptomatic DVT. Half of the 90 subjects also had silent pulmonary emboli. Subjects were randomized to anticoagulation or NSAIDs and there was 1 fatal PE during the study period (anticoagulation group). In 1960, Barritt and Jordan performed a randomized trial evaluating anticoagulation for presumed PE. While the study is often cited

2010 theNNT

284. Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis

Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

285. [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke]

[Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke] Intravenos trombolytisk behandling av hjerneinfarkt i akuttfasen og sekundaer blodproppforebyggende behandling (platehemmende behandling og antikoagulasjonsbehandling) etter hjerneslag [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment (...) ) after stroke] Intravenos trombolytisk behandling av hjerneinfarkt i akuttfasen og sekundaer blodproppforebyggende behandling (platehemmende behandling og antikoagulasjonsbehandling) etter hjerneslag [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke] Wisloff T, Hamidi V, Ringerike T, Harboe I, Klemp M Record Status This is a bibliographic record of a published health technology assessment

2010 Health Technology Assessment (HTA) Database.

286. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Full Text available with Trip Pro

Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Hawryluk GW, Austin JW, Furlan JC, Lee JB, O'Kelly C, Fehlings MG CRD summary The review acknowledged the low quality of the evidence, but suggested (...) that it may be important to restart anticoagulation earlier than thought previously with the timing and intensity modified based on perceived individual risks. Further research was needed. Evidence limitations suggest that the findings should be interpreted with caution, but the authors' recommendation for further research seems appropriate. Authors' objectives To identify the optimal timing and intensity for anticoagulation re-initiation following central nervous system haemorrhage in patients with high

2010 DARE.

287. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Full Text available with Trip Pro

Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Finlay M, Sawhney V, Schilling R, Thomas G, Duncan E, Hunter R, Virdi G (...) readmission due to bleeding-related complications, while three on LMWH and 11 on warfarin underwent transoesophageal echocardiogram before the procedure. The total costs were £125 for LMWH and £108.5 for warfarin patients (p<0.0001). Authors' conclusions The authors concluded that uninterrupted warfarin was safer and more cost-effective for anticoagulation in catheter ablation for typical atrial flutter, compared with changing to LMWH before the procedure. CRD commentary Interventions: The two options

2010 NHS Economic Evaluation Database.

288. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery.

Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed (...) to lower the patient anticoagulation dose when performing minor dental surgery. Francesco Chiappelli Ph.D; Michael Montgomery DDS; Juan F. Yepes DDS, MD, MPH, FDS RC . Overview Systematic Review Conclusion Continuing the regular dose of warfarin therapy during minor dental surgery does not appear to increase the risk of bleeding compared to discontinuing or reducing the dose. Critical Summary Assessment A limited to RCTs finds that the rates of clinically significant nonmajor bleeding and minor

2009 ADA Center for Evidence-Based Dentistry

289. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery.

Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed (...) to lower the patient anticoagulation dose when performing minor dental surgery. Francesco Chiappelli Ph.D; Michael Montgomery DDS; Juan F. Yepes DDS, MD, MPH, FDS RC . Overview Systematic Review Conclusion Continuing the regular dose of warfarin therapy during minor dental surgery does not appear to increase the risk of bleeding compared to discontinuing or reducing the dose. Critical Summary Assessment A limited to RCTs finds that the rates of clinically significant nonmajor bleeding and minor

2009 ADA Center for Evidence-Based Dentistry

290. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery.

Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed (...) to lower the patient anticoagulation dose when performing minor dental surgery. Francesco Chiappelli Ph.D; Michael Montgomery DDS; Juan F. Yepes DDS, MD, MPH, FDS RC . Overview Systematic Review Conclusion Continuing the regular dose of warfarin therapy during minor dental surgery does not appear to increase the risk of bleeding compared to discontinuing or reducing the dose. Critical Summary Assessment A limited to RCTs finds that the rates of clinically significant nonmajor bleeding and minor

2009 ADA Center for Evidence-Based Dentistry

291. Improved Oral Anticoagulation After a Dietary Vitamin K-Guided Strategy. A Randomized Controlled Trial Full Text available with Trip Pro

Improved Oral Anticoagulation After a Dietary Vitamin K-Guided Strategy. A Randomized Controlled Trial Dietary vitamin K is thought to be an important factor that interferes with anticoagulation stability, but the clinical applicability of this interaction has not been evaluated adequately in prospective studies.In a randomized controlled trial that enrolled outpatients with a recent international normalized ratio (INR) outside the therapeutic target, we compared 2 strategies to optimize long (...) -term oral anticoagulation: (1) a conventional approach based on changes in anticoagulant prescription and (2) a dietary vitamin K-guided strategy based on simple modifications of the amount of vitamin K-rich foods ingested per week. The primary efficacy end point was the percentage of patients who achieved a prespecified INR target at 90 days after randomization. Study population (n=132) predominantly included men with mechanical heart prostheses (58%) or atrial fibrillation (35%). Over time

2009 EvidenceUpdates Controlled trial quality: uncertain

292. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Full Text available with Trip Pro

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Guidelines recommend warfarin use in patients with atrial fibrillation solely on the basis of risk for ischemic stroke without antithrombotic therapy. These guidelines rely on ischemic stroke rates observed in older trials and do not explicitly account for increased risk for hemorrhage.To quantify the net clinical benefit of warfarin therapy in a cohort of patients with atrial fibrillation.Mixed retrospective

2009 Annals of Internal Medicine

293. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Full Text available with Trip Pro

Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the live-birth rate in subsequent pregnancies in women with either inherited thrombophilia or unexplained recurrent miscarriage.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without (...) apparent causes other than inherited thrombophilia.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (April 2008), the Cochrane Central Register of Controlled Trials (The Cochrane Library 2007, Issue 1), MEDLINE (January 1966 to March 2007), and EMBASE (1980 to March 2007). We scanned bibliographies of all located articles for any unidentified articles.Randomised and quasi-randomised controlled trials that assessed the effect of anticoagulant treatment on the live-birth rate

2009 Cochrane

294. [Selfmonitored anticoagulant therapy]

[Selfmonitored anticoagulant therapy] Selvmonitoreret blodfortyndende behandling – en kommenteret udenlandsk medicinsk teknologivurdering [Selfmonitored anticoagulant therapy] Selvmonitoreret blodfortyndende behandling – en kommenteret udenlandsk medicinsk teknologivurdering [Selfmonitored anticoagulant therapy] Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). Selvmonitoreret blodfortyndende behandling – en kommenteret udenlandsk medicinsk teknologivurdering. [Selfmonitored anticoagulant therapy] Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). 2(1). 2009 Authors' conclusions This report is a Danish commented version of an British HTA. The British HTA compares

2009 Health Technology Assessment (HTA) Database.

295. Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation

Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation Article Text Therapeutics Oral anticoagulant therapy safely prevented stroke in older patients with atrial

2009 Evidence-Based Medicine

296. Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin

Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarinOral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) anticoagulation after receiving warfarinOral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Article Text Therapeutics Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Statistics from Altmetric.com STUDY DESIGN Design: randomised, placebo-controlled trial. ClinicalTrials.gov NCT00143715

2009 Evidence-Based Medicine

297. Combined leg compression and anticoagulants effective in preventing venous thromboembolism

Combined leg compression and anticoagulants effective in preventing venous thromboembolism PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Combined leg compression and anticoagulants effective in preventing venous thromboembolism Clinical question Compared with single modalities, how effective is intermittent pneumatic leg compression combined with pharmacological prophylaxis in preventing (...) venous thromboembolism (VTE) in high-risk patients? Bottom line Compared with compression alone, combined prophylactic modalities significantly decrease the incidence of VTE, ie, symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT). Compared with pharmacological prophylaxis alone, combined modalities significantly reduce the incidence of DVT but the effect on PE could not be determined because of the lack of events in the included studies. Anticoagulants used in the trials included

2009 Cochrane PEARLS

298. Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped

Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped Article Text Clinical prediction guide Review: D-dimer concentrations predict risk

2009 Evidence-Based Medicine

299. Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Full Text available with Trip Pro

Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Romualdi E, Micieli E, Ageno W, Squizzato A CRD summary The optimal management of oral anticoagulant therapy after intracranial bleeding secondary (...) to vitamin K antagonist use in patients with a mechanical heart valve was investigated. The authors concluded that restarting or stopping anticoagulant therapy for a few days appeared to be safe, but the quality of evidence was low. The review was generally well conducted and the authors' conclusions appear appropriate. Authors' objectives To investigate the optimal management of oral anticoagulant therapy after intracranial bleeding secondary to the use of vitamin K antagonists in patients

2009 DARE.

300. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis

Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE CRD summary This generally well-conducted review found no apparent increase in risk of bleeding associated (...) and underwent an elective dental procedure were eligible if they compared continuance on the usual dose of warfarin with reduction or cessation of usual warfarin dose. Eligible studies had to assess at least one of arterial or venous thromboembolism or postoperative bleeding (major, minor or clinically significant non-major). All of the included studies assessed patients who underwent dental extractions (single or multiple teeth). Most patients required anticoagulation therapy for prosthetic heart valves

2009 DARE.